DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2263560/sage-therapeutics-sage-q1-earnings-miss-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2263560 Apr 26, 2024 - Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line. 0

https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685 Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement. 0

https://www.fool.com/earnings/call-transcripts/2024/04/24/biogen-biib-q1-2024-earnings-call-transcript/?source=iedfolrf0000001 Apr 24, 2024 - BIIB earnings call for the period ending March 31, 2024. 0

https://www.zacks.com/stock/news/2258435/what-s-in-store-for-biogen-biib-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258435 Apr 19, 2024 - Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate. 0

https://www.zacks.com/stock/news/2258367/gear-up-for-biogen-biib-q1-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2258367 Apr 19, 2024 - Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024. 0

https://www.zacks.com/stock/news/2257958/sage-sage-down-20-on-parkinson-s-study-missing-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257958 Apr 18, 2024 - Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo. 0

https://www.zacks.com/stock/news/2256869/biogen-inc-biib-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2256869 Apr 17, 2024 - Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2247453/omega-therapeutics-inc-omga-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2247453 Mar 28, 2024 - Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://seekingalpha.com/article/4679198-biogen-inc-biib-stifel-2024-virtual-cns-days-transcript?source=feed_sector_transcripts Mar 19, 2024 - Biogen Inc. (NASDAQ:NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ETCompany ParticipantsPriya Singhal - Head of Development... 0

https://www.zacks.com/stock/news/2239569/biogen-inc-biib-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2239569 Mar 12, 2024 - Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close. 0